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Multimodal therapy is often used in oncology to overcome dosing limitations and chemoresistance. Recently,
combination immunoradiotherapy has shown great promise in a select subset of patients with colorectal cancer
(CRC). Furthermore, molecularly targeted agents delivered in tandem with immunotherapy regimens have been
suggested to improve treatment outcomes and expand the population of responding patients. In this study,
radiation-sensitizing small molecules niraparib (PARP inhibitor) and HS-173 (PI3K inhibitor) are identified as a
novel combination that synergistically enhance toxicity and induce immunogenic cell death both in vitro and in
vivo in a CRC model. These inhibitors were co-encapsulated in a polymer micelle to overcome solubility limita-
tions while minimizing off-target toxicity. Mice bearing syngeneic colorectal tumors (CT26) were administered
these therapeutic micelles in combination with X-ray irradiation and anti-CTLA-4 immunotherapy. This combi-
nation led to enhanced efficacy demonstrated by improved tumor control and increased tumor infiltrating lym-
phocytes. This report represents the first investigation of DNA damage repair inhibition combined with radiation
to potentiate anti-CTLA-4 immunotherapy in a CRC model.1. Introduction
The aggressive proliferation and spread of late-stage cancers are
seldom controlled by one therapeutic modality alone. Current clinical
oncology practice typically employs two or more therapies sequentially
or concurrently, which necessitates a balance of treatment safety and
efficacy. Patients diagnosed with advanced disease often undergo a
combination of radiation, chemo-, immuno-, and molecularly targeted
therapies. In the case of colorectal cancer (CRC), late-stage presentation
occurs in 60% of patients when curative surgical resection is not feasible,
thus requiringmultimodality treatment [1]. The advanced age of patients
with CRC (average 65–74 yrs) at diagnosis further complicates treatment
and highlights the need for safer therapeutic regimens [1].
Immunotherapy has begun to address the need in CRC treatment for
effective tumor killing with increased durability. Specifically, immune
checkpoint blockade (ICB) recently demonstrated improved survival forutical Sciences, College of Pharm
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0 September 2020; Accepted 8 O
evier Ltd. This is an open access aa subset of patients with CRC compared with traditional chemo- and
radiation therapy (RT) [2–5]. As a result, the combination of ipilimumab
(anti-CTLA-4) and nivolumab (anti-PD-1) was approved for microsatel-
lite instability (MSI)-high or mismatch repair (MMR)-deficient metastatic
CRC in 2018 [6]. Although promising, two major limitations persist for
this ICB-based therapy. First, the approved combination resulted in
immune-related adverse effects (irAEs) in the majority of patients. In this
case and others, CTLA-4 antibodies are dose limited due to the high
occurrence of grade 3 and 4 irAEs [3,7]. Second, positive outcomes are
limited to the small subset of patients (MSI-high andMMR-deficient) who
have high mutational burden and increased metastases [6].
The integration of DNA damaging agents, such as ionizing radia-
tion (IR) and chemotherapy, into immunotherapy regimens to poten-
tiate immunogenic cell death (ICD) and subsequently synergistically
enhance therapy has been of significant interest recently [8]. In the
context of CRC, the addition of poly-ADP ribose polymerase (PARP)acy, Oregon State University, Portland, 97201, OR, USA.
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[9]. Taken together, this presents an opportunity to combine immu-
notherapy and RT with PARP inhibition for enhanced patient re-
sponses and outcomes. On a molecular level, PARP is responsible for
repairing single strand breaks (SSBs) resulting from defects in the DNA
damage response (DDR) pathway or induced by exogenous agents,
such as IR. In addition to preventing the repair of DNA damage, PARP
inhibitors play an activating role in the immunostimulatory cyclic
GMP-AMP synthase–stimulator of interferon genes pathway [10]. In-
hibition of PARP in irradiated cells has been shown to enhance effi-
cacy by both increasing type 1 interferon production and
radiation-induced SSB accumulation [11]. Ultimately, these pro-
cesses lead to cell death and the potential to convert so-called ‘cold’
non-immunogenic tumors to ‘hot’ immunogenic tumors.
As a monotherapy, the utility of PARP inhibitors is limited to pa-
tients with defective homologous recombination DNA repair. To
broaden their application, phosphoinositide-3-kinase (PI3K) inhibitors
have been shown to sensitize tumors with proficient DDR to PARP
inhibition [12–14]. Furthermore, in combination with RT, we and
others have previously demonstrated the radiosensitizing potential of
combining PI3K and PARP inhibitors [15–17]. Here, for the first time
in a CRC model, we performed a combinatorial analysis of several
PARP and PI3K inhibitors to determine the optimally synergistic and
radiosensitizing pair. Upon screening in an MMR proficient CRC cell
line both with and without RT, niraparib (N), a PARP inhibitor FDA
approved for ovarian cancer, and HS-173 (H), an experimental drug
developed as an imidazopyridine-based PI3Kα inhibitor, were identi-
fied as a potent combination, hereinafter referred to as N-H [18].
Unfortunately, similar to many other small molecule inhibitors, N
and H are extremely hydrophobic, necessitating the use of potentially
cytotoxic (co-)solvents and excipients. These formulation vehicles,
such as Cremophor EL, have limited solubilization capabilities and
narrow the already restricted therapeutic window [19]. Polymeric
micelles are an ideal alternative drug carrier; Genexol-PM is one such
example where polymeric micelles outperformed Cremophor EL in
terms of patient response and toxicity when delivering paclitaxel [19].
Here we use poly(2-oxazoline) (POx) based amphiphiles to encapsu-
late N-H in a micelle-based formulation to improve solubility and
facilitate in vivo drug delivery. POx polymers are a promising class of
solubilizing agents with physiochemical properties optimized for
pharmaceutical formulations [20,21]. Recently, the utility of POx
polymers has grown due to their facile synthesis and tunability. In
particular, ABA-type triblock copolymers bearing a hydrophilic shell
(poly(2-methyl-2-oxazoline)) and differing hydrophobic cores enable
high encapsulation efficiency in a micellar formulation for various
drugs [22]. In addition to improved pharmacokinetics and bio-
distribution, the novel N-H POx formulation maintains favorable sta-
bility and cellular uptake characteristics, while addressing the main
aim of increasing on-target drug concentrations with limited off-target
toxicities.
In this study, we investigated the utility of N-H POx to enable a
multipronged CRC treatment strategy. In addition to prerequisite
physical and chemical characterization, a preclinical evaluation was
performed in a syngeneic mouse model to assess both tumor cell
killing of adding N-H POx and IR to CTLA-4 therapy (α-CTLA-4), and
the treatment's overall safety. Codelivery of PARP and PI3K inhibitors
may both selectively induce an MMR-deficient state in an MMR-pro-
ficient cell line and induce ICD. Therefore, exploiting PARP/PI3K in-
hibition has the potential to expand the responding population to
include microsatellite stable patients with CRC. Herein, we demon-
strate that this novel PARP/PI3K inhibitor combination delivered via
POx micelles provides an added benefit to anti-CTLA-4 immuno-
therapy in a syngeneic murine CRC model.2
2. Experimental
2.1. Materials
The POx polymer, A-PBzOx-A, was synthesized as previously
described [45]. Crystal violet dye, acetonitrile high-performance liquid
chromatography (HPLC grade), TFA, and methanol (HPLC grade) were
purchased from Fisher Scientific (Hampton, NH, USA). Cyanine 7.5
carboxylic acid was purchased from Lumiprobe (Hunt Valley, MD, USA),
niraparib was purchased from MedChemExpress (Monmouth Junction,
NJ, USA) and HS-173 was purchased from MedChemExpress and Selleck
Chem (Houston, TX, USA). Anti-CTLA-4 antibody (9D9 clone) was pur-
chased from Bio X Cell (West Lebanon, NH). Phosphate-buffered saline
(PBS) 1X and RPMI 1640 medium were purchased from Corning Inc.
(Corning, NY, USA). Amicon Ultra centrifugal filters and 10% (v/v)
neutral buffered formalin were obtained from Millipore Sigma (Bur-
lington, MA, USA). DAPI (40,6-Diamidino-2-Phenylindole, Dilactate) and
Alexa Fluor™ 488 Phalloidin were purchased from Thermo Fisher Sci-
entific (Carlsbad, CA, USA). CT26 cells were purchased from ATCC and
maintained in RPMI 1640 medium supplemented with 10% (v/v) fetal
bovine serum and 1% (v/v) penicillin/streptomycin.
2.2. In Vitro cytotoxicity
To determine the efficacy of PARP and PI3K combinations, CT26 cells
were seeded at 2000 cells per well in two replicate 96-well plates per
combination and allowed to settle overnight. Cells were then treated with
free drugs (alone or in combination) at various concentrations ranging
from 0.01 μM to 50 μM (Fig. 1B and S1) and incubated at 37 C. After
24 h, a radiation dose of 4 Gy was administered to one of the replicate
plates. After 48 h, cells were washed once with PBS, then viability was
determined by Alamar Blue (Invitrogen, Eugene, OR, USA). Sample
fluorescence at 530 and 590 nm was measured using an Infinite M200
Pro plate reader (Tecan US Inc, Morrisville, NC, USA). Cell viability was
normalized to untreated cells, and IC50 values were computed by fitting
the data to a four-parameter dose response, variable slope model using
GraphPad Prism 8. Combination indexes (CIs) were determined using
CompuSyn (ComboSyn Inc, Paramus, NJ, USA), where cell viabilities less
than 90% and greater than 10% were the only Fa values used. All cell
viability measurements were performed in triplicate.
Free N-H, E POx, and N-H POx viability were run the same as described
previously. Concentrations of N-H (solubilized in dimethyl sulfoxide
(DMSO) or encapsulated in micelle) ranged from 0.0003 μM to 100 μM. E
POxdosingmatched that of theN-HPOx in terms of polymer concentration.
2.3. In Vitro ICD assay
CT26 cells were plated in at 25,000 cells/well in an 8-well chamber
slide andallowed to settle for 24h.At 24h,mediawas replacedwithmedia
containingN-H (0.4 μMeach), oxaliplatin (50 μM) as a positive control, or
media as a negative control. Cells were incubated for 6 h, and then cells
werewashedwithPBS twice and formalinfixed. Cellswere incubatedwith
Hoechst (33,342, Invitrogen) diluted in RPMI at 5 μg/mL for 10 min,
followed by incubation with wheat germ albumin (WGA) (W11261,
Invitrogen)diluted inHank's Balanced Salt Solutionat 5 μg/mL to stain the
nuclei and cell membrane, respectively. Cells were then incubated with a
rabbit anti-Calreticulin antibody (ab2907, Abcam) at a 1:200 dilution for
30 min on ice in non-permeabilizing antibody dilution buffer (1% BSA in
PBS). Then, cells were washed with PBS and incubated with a goat anti-
rabbit IgGH&L (Cy5) antibody (6564,Abcam)at a 1:1000dilution innon-
permeabilizing antibody dilution buffer in the dark for 30 min at room
temperature. Finally, cells were once more washed with PBS and imaged
using an EVOS FL Auto microscope at 40magnification.
Fig. 1. Evaluation of cell viability and
drug synergy. (A) Chemical structures of
PARP and PI3K inhibitors (B) In vitro toxicity
of free drug combination treatment with ( )
and without ( ) radiation. Radiation only
controls are shown with a dotted line. (C)
Combination index (CI) values with radiation
were calculated and plotted to evaluate the
synergy of the combination with radiation.
CI > 1 represents antagonism, CI ¼ 1 repre-
sents additivity, and CI > 1 represents syn-
ergy. The dashed line is for reference at
y ¼ 1. The full screen combination data are in
Fig. S1. The N and H combination was chosen
due to data in both (B) and (C).
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Polymeric micelles were prepared via a modified nanoprecipitation
method. To formulate N-H POx, A-PBzOx-A polymer was solubilized in
ethanol at 300 mg/mL, while niraparib and HS-173 were solubilized
individually in DMSO at 30 mg/mL. An organic layer was prepared by
first combining N and H, then adding the polymer and excess ethanol,
followed by sonication. To achieve micelle formation, PBS was added to
the organic layer at a 9:1 PBS:organic v/v ratio for a polymer concen-
tration of 5 mg/mL and drug concentrations of 1 mg/mL each. The mi-
celles were subsequently filtered at 4696  G for 10 min and 22 C using
a 10,000 kDaMW cutoff Amicon Ultra centrifugal filter to remove solvent
and free drug/polymer. Following centrifugation, the micelles were
resuspended to the precentrifugation volume in PBS. Empty micelles (E
POx) were prepared in the same manner with equal DMSO in the place of
N and H. Cy7.5 POx (Cy7.5 loaded micelles) were also prepared as
described previously, substituting drug for a stock of Cy7.5 in DMSO at
1 mg/mL. The final concentration of the Cy7.5 in the micelles was
0.01 mg/mL.
Purified micelles were characterized by DLS, transmission electron
microscopy (TEM). DLS was performed using a Malvern Nano ZSP
(Malvern Panalytical, Malvern, UK) to determine the size, zeta potential,
and polydispersity for micelle formulations. TEM images were obtained
with a Tecnai iCorr while cryoTEM images were obtained with a Titan
Krios Cryo-TEM (FEI, Hillsboro, OR, USA). Drug loading was quantified
using a Shimadzu SPD-20A HPLC instrument (Torrance, CA, USA)
equipped with a UV/Vis detector and an Agilent Zorbax Rapid Resolution
SBC-18 column (4.6  100 mm 3.5 μm; Santa Clara, CA, USA). The
filtrate from centrifugally filtered micelles was diluted in a 100-fold in
MeOH and analyzed by HPLC. To ensure the drug was properly quanti-
fied, the filter was flooded with 2 mL MeOH twice and run on HPLC to
ensure all drug was accounted for. All samples were compared with a
standard curve of N and H to determine concentration. The samples were3
run with a 65%–70% methanol in water (0.1% TFA) gradient over 6 min
with a flow rate of 1 mL/min and a 311 nm detection wavelength. Nir-
aparib eluted first (retention time ¼ 1.3 min) with HS-173 following
(retention time ¼ 2.3 min).
2.5. In vitro drug release
Drug release for the two inhibitors was determined by loading mi-
celles into Slide-A-Lyzer MINI dialysis microtubes with a molecular
weight cutoff of 2 kDa. N-H POx samples were dialyzed against a 120-fold
excess of buffer (pH 5.5, 6.8, or 7.4 PBS) with gentle stirring in a water
bath at 37 C. Samples of 1 mL were collected at designated time points
between 0 and 360 h, diluted in methanol (1:4), and concentrations
determined by HPLC as previously described previously. Drug release
profiles were plotted as a cumulative percentage of total drug release
versus time. All drug release measurements were performed in triplicate.
2.6. In vitro cellular uptake study
CT26 cells were seeded into a 96-well plate (6000 cells/well) and
allowed to settle for 24 h. When cells had settled, Cy-7.5 POx and free
Cy7.5 (both at a constant 1000 ng/mL concentration) were added in
fresh media at various time points between 0 and 24 h. At study end
point, the cells were washed with PBS, formalin fixed, and imaged on
EVOS FL Auto microscope at 20 magnification. Images were processed
using ImageJ, and the average pixel intensity of 6 images (2 per well) for
each time point were calculated and graphed.
2.7. Clonogenic assay
The radiosensitizing ability of N-H POx was assayed by seeding
CT26 cells into T25 flasks, which were allowed to settle overnight and
subsequently treated for 24 h. After therapeutic incubation, cells were
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Cabinet Irradiator, Faxitron, 130 kV, 5 mA, 0.5 mm aluminum filter,
~1.2 Gy/min). The irradiated cells were then allowed to proliferate for 7
days. The number of cells seeded varied based on the dose of radiation
(0–8 Gy) and drug treatment condition (media only, 0.4 μM free nir-
aparib, 0.4 μM free HS-173, 0.3/0.4 μM free niraparib/HS-173, 0.3/
0.4 μM N-H POx, and 1.8 mg/mL E POx further diluted to the same
concentration as N-H POx were dosed at). The plating numbers ranged
from 100 cells/well for no treatment to 3000 cells/well for 8 Gy plus N-H
POx. At study end, cells were washed with PBS, formalin fixed, and
stained with 0.01 mg/mL crystal violet dye to identify colonies of greater
than 50 cells. The survival fraction (SF) was determined by calculating an
average plating efficiency (PE) for each treatment and dividing that value
by the average PE of the unirradiated control for each drug treatment.
Here, PE is the number of colonies formed for a condition divided by the
number of cells seeded for that condition.
2.8. Immunofluorescent γH2AX DNA damage assay
To evaluate DNA double-strand breaks (DSBs), CT26 cells were plated
at 120,000 cells/well in two gelatin-coated 4-well chamber slides and
allowed to settle for 24 h. At 24 h, media was replaced with media
containing N-H, N-H POx, E POx, or media only. Cells were incubated
with these treatments (Fig. 4) for 20 h at which point one of the plates
was irradiated with 2 Gy (CellRad). Fifteen minutes after irradiation,
cells were washed with PBS and formalin fixed. After fixing, cells were
again washed with PBS, then blocked and permeabilized using 5% goat
serum and 0.3% Triton X-100. After blocking and permeabilization, cells
were incubated with a rabbit anti-Phospho-Histone H2AX (Ser139)
Antibody (#2577, Cell Signaling Technologies) at a 1:800 dilution for 2 h
at room temperature in antibody dilution buffer (1% BSA and 0.3%
Triton X-100 in PBS). Then, cells were washed with PBS and incubated
with a goat antirabbit IgG H&L (Cy 5) antibody (6564, Abcam) at a
1:1000 dilution in antibody dilution buffer in the dark overnight at 4C.
Finally, the cells were stained with DAPI and Phalloidin, washed once
more with PBS, and imaged using an EVOS FL Auto microscope at 20
magnification. DNA quantification was assessed using CellProfiler over-
laying DAPI stained nuclei with Cy5-stained γH2AX foci for a foci/cell
count using a modified speckles pipeline.
To analyze γH2AX by flow cytometry, 500,000 cells were plated in
6-well plates. After 24 h, cells were dosed with N-H, N-H POx, E POx,4
or media in triplicate. After 20 h of incubation, half of the plates were
irradiated with 2 Gy. Fifteen minutes later, cells were detached from
the plate using trypsin/EDTA and diluted in media. The cells were
pelleted at 500g for 5 min, the media was aspirated, and the cells
dispersed in PBS. This process was repeated this time substituting
formalin for PBS to allow fixation for 15 min. To remove fixative, cells
were again pelleted at 500g for 5 min, the formalin aspirated and
cells dispersed in antibody dilution buffer containing the above γH2AX
primary antibody at 1:800 dilution. After 2 h at room temperature, the
antibody was removed by pelleting, then the cells were washed and
redispersed in a PBS solution of DAPI. Ten minutes later, the cells
received one final spin at 500g for 5 min, the DAPI was aspirated, the
cells were resuspended in PBS and strained through a filter cap into
8 mL flow cytometry tubes. Samples were assessed using a MACS-
Quant flow cytometer (Miltenyi Biotec, Cologne, Germany). Fluores-
cence of no treatment, E POx, N-H, N-H POx, and/or irradiated cells
was determined using a 632 nm excitation laser line, with a
655–730 nm emission filter set. Forward scattering/side scattering
were used to identify live, single cells passing through the detector,
and 100,000 cells were evaluated in the flow cytometer for each
sample to build a distribution.
2.9. In vivo studies
All animal studies were approved by and conducted in accordance
with the guidelines of the Institutional Animal Care and Use Committee
(IACUC) of Oregon Health and Sciences University. For all imaging
studies and when noted, mice were anesthetized using 2–3% isoflurane
(Piramal Enterprises Limited, Telangana, India).
2.10. Establishment of tumor xenografts in mice
Subcutaneous CT26 tumor xenografts were established by injecting
cell suspensions (150,000 cells) into the right flanks of BALB/c mice
(Charles River Laboratories, Wilmington, MA).
2.11. In vivo ICD
One female BALB/c mouse was implanted with 150,000 CT26 cells on
the right hind flank. 12 days after implant, the mouse had developed two
sizable tumors. One of the tumors was injected with N-H suspended inFig. 2. Immunogenic cell death induction
in vitro and in vivo. (A) Visualization of
immunogenic cell death by surface (wheat
germ albumin membrane stain) exposure of
calreticulin. (B) Quantified calreticulin
expression for each treatment group from
images in (A). * denotes significance
(p < 0.05) (C) Macroscopic view of DMSO-
treated tumor demonstrates dense tumor
tissue (purple) with a small necrotic region
(pink). (D) Microscopic view of rectangle in
(C) which demonstrates the accumulation of
leukocytes (purple specks) at the necrotic
region (pink) periphery with minimal infil-
tration. (E) Macroscopic view of N-H treated
tumor demonstrates less dense tumor tissue
(purple) and a larger necrotic region (pink).
(F) Microscopic view of (E) demonstrates a
larger leukocyte (purple specks) influx to the
necrotic region (pink). le represents the
leading edge of immune infiltration, and nc
represents the necrotic region. Arrows
represent leukocytes and arrowheads repre-
sent nuclear fragments. Scale bars represent
1000 μm (black) and 100 μm (white).
Fig. 3. Particle characterization. (A) Sche-
matic representation of formulation method
showing structure of drugs, polymers, and mi-
celles. (B) Intensity average DLS measurements
for E and N-H POx. (C) Negative stain TEM image
of N-H POx demonstrates a particle size of about
14 nm. Scale bar represents 100 nm. (D) In vitro
toxicity of free N-H compared with E and N-H
POx, with (open symbols) and without radiation
(closed symbols). (E) Drug release profile for N-H
POx under sink conditions at pH 7.4 PBS as
determined by HPLC.
Fig. 4. In vitro radiation and N-H combi-
nation damage. (A) Representative γH2AX
images demonstrate the difference in num-
ber of foci and overall signal intensity for
various treatments with and without radia-
tion. Scale bar represents 100 μm. (B)
Quantification of γH2AX puncti per cell from
images in (A). (C) Histograms of treated
samples analyzed by flow cytometry show
shift in γH2AX intensity. (D) Clonogenic
assay demonstrates the radiosensitizing po-
tential of N-H POx over free N-H or E POx at
various radiation doses. Curves are fit using
the linear quadratic equation. No colonies
formed in the N-H POx treatment group at 6
gray.
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administered at a dose estimated to be deliverable using the N-H POx
formulation by IV, assuming that a maximum of 10% would reach the
tumor. Tumors were harvested 24 h later and formalin fixed at 4 C
overnight before being transferred to 70% ethanol. At this point, tissues
were submitted to the OHSU Histopathology Shared Resource Core for
tissue clearing, slicing (5 μm), and subsequent hematoxylin and eosin
(H&E) staining. Imaging was performed on a Zeiss Axio Scan.Z1 Slide
Scanner by the OHSU Advanced Light Microscopy Core at 20 .
2.12. Evaluation of safety in mice
Toxicity of the various treatment regimens were evaluated in six-
week-old, female, tumor-bearing BALB/c mice aged 6-weeks. Mice were
treated with E POx or N-H POx and each of the following conditions:
alone, with radiation only, with CTLA-4 only, or with both radiation and
CTLA-4 as detailed in Fig. 5A. Fourteen days after the start of treatment,
mice were anesthetized, and blood was collected into 1 mL lithium
heparin coated tubes (Grenier Bio-One, Kremsmünster, Austria) via car-
diac puncture and stored at 4 C before hematology and complete blood
counts (CBC) analysis by IDEXX Laboratories.
2.13. Evaluation of antitumor efficacy and long-term effects in mice
For the first in vivo study (Fig. 5), 76 six-week old BALB/c mice were
injected subcutaneously with 150,000 CT26 cells on the right hind flank.6
Seven days after CT26 tumor inoculation, 41 mice were randomized to
receive α-CTLA-4 treatment and injected intraperitoneally with 250 μg
anti-CTLA-4 antibodies. Five days later, all 76 mice were randomized
into one of eight treatment groups (n  7 per group, Fig. S9B). These
eight treatment groups were further randomized into a treatment effi-
cacy/safety study (32 mice, n¼ 4 per group) and survival (44 mice, n 3
per group) study. On the day that the first mouse from the 32 mice
randomized to treatment efficacy/safety reached an endpoint all 32 mice
were sacrificed, with organs and blood harvested to evaluated safety and
efficacy. On day 14, two mice reached an endpoint, so all 32 mice were
sacrificed with the two who reached endpoints being included in the
survival study (bringing the total to 46 mice) but all 30 other mice being
excluded as they would have survived longer. As the 44 mice in the
survival study and the 32 all survived to day 14, these mice were all
included in the tumor growth curves.
For tumor volume/efficacy/survival studies, treatment groups were
as follows: (1) E POx control, (2) E POx þ IR, (3) niraparib and HS-173
micelles (N-H POx), (4) N-H POx þ IR, (5) E POx þ α-CTLA-4, (6) E
POx þ IR þ α-CTLA-4, (7) N-H POx þ α-CTLA-4, or (8) N-H
POx þ IR þ α-CTLA-4. Mice were administered micelles via tail vein
injection 3  on days 0, 2, and 4 for a total of 10.73 mg/kg HS-173
and 11.07 mg/kg niraparib. Mice in groups 2, 4, 6, and 8 were irra-
diated with 1 Gy on days 0, 2, and 4 for a total of 3 Gy. Radiation was
delivered (CellRad, Faxitron, 130 kV, 5 mA, 0.5 mm aluminum filter,
~1.2 Gy/min) selectively to tumors by covering mice with half-moon
cutout lead shields (Precision X-Ray, North Branford, CT). Mouse bodyFig. 5. In vivo efficacy and survival studies.
(A) Dosing schedule for both the efficacy and
survival studies. (B) Relative tumor volume
curves for mice in efficacy study treated with
various therapeutic agents after treatment
regimen in (A). (C) Polymer carrier (E POx) and
N-H POx–treated tumors from day 14 stained
with H&E, proliferation (Ki67 in brown), and
apoptosis (CC3 in brown). Scale bar (100 μm) is
representative for all images. (D) Relative tumor
volume for α-CTLA-4 treatment groups from sur-
vival study. Curve ends when first mouse in
treatment group reaches the endpoint. (E)
Kaplan-Meier survival curve for α-CTLA-4 treat-
ment groups with differences in survival calcu-
lated in accordance with the logrank test.
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recorded 2–3 times per week. As mentioned previously, tumor mea-
surements from both the survival and efficacy groups were used to
generate relative tumor growth curves up to day 14. On day 14, the
first mouse reached an endpoint, and the efficacy mice were sacrificed.
Terminating the efficacy study when the first mouse reached an
endpoint allowed for a direct comparison of tumor growth inhibition
based on tumor volume curves, as well as endpoint tumor mass and
histologic parameters. Mice were euthanized per IACUC guidelines
once tumors began to develop cavitated ulcerations, weight loss
reached 20% of starting weight, or any diameter reached 2 cm. Car-
diac puncture was used to collect terminal blood samples for clinical
chemistry. Organs from at least one mouse per treatment group were
harvested for H&E staining to evaluate therapeutic toxicity and hyp-
oxia. In addition, tumors from these mice were stained for Ki67 and
Cleaved Caspase-3 to evaluate proliferation or apoptosis, respectively
(see Tumor Histology below). A Kaplan-Meier curve was developed for
each treatment group to examine differences in survival.
For the second in vivo study, 28 mice were implanted with CT26
tumors as described previously. Half of the mice were injected with
CTLA-4 antibodies 7 days after tumor implant (mimicking study 1)
and the other half 12 days after tumor implant, concurrent with the
start of radiation and micelles. The mice followed the same radia-
tion and micelle dosing as aforementioned, with caliper measure-
ments of the tumors 2–3 times weekly. The mice tumor growth
curves (Fig. 6B) were carried out until one of the mice reached an
endpoint in one particular group, rather than all groups. Individual
growth curves were carried out until all of the mice reached an
endpoint or were cured. At day 58, cured mice were challenged with
150,000 CT26 cells on the right hind flank, similarly to initial tumor
inoculation. The mice were monitored for 30 days for regrowth of a
tumor.
2.14. Tumor histology
Tumors from mice in the tumor volume treatment protocol were
collected and formalin fixed at 4 C overnight before being transferred
to 70% ethanol and submitted to the OHSU Histopathology Shared
Resource Core for tissue clearing, slicing (5 μm), and subsequent
staining. Stains performed were hematoxylin and eosin (H&E),
Caspase-3 (Promega), and Ki67 (Cell Marque). Antibodies were7
diluted in accordance with supplier recommendations before staining.
Imaging was performed on a Zeiss Axio Scan.Z1 Slide Scanner by the
OHSU Advanced Light Microscopy Core at 20 .
2.15. Statistical analysis
All data are expressed as mean  SEM. Statistical differences and
significance were evaluated using one-way ANOVA, two-way ANOVA, or
t-test in the Graph Pad Prism 8 software pack. p < 0.05 was considered
statistically significant and represented by *.
3. Results and discussion
3.1. PARP and PI3K inhibitor combination screen and cell viability
Currently, only antiangiogenic therapeutics are approved and used as
molecular therapies for CRC. As mentioned previously, PARP is under
investigation as a target for CRC treatment, while PI3K is often upregu-
lated in CRC making the combination of inhibitors targeting these pro-
teins a promising therapeutic strategy [23–26]. To optimize this potential
therapy, a combinatorial array of four PARP and three PI3K inhibitors
were evaluated for synergy in murine CT26 cells (Fig. S1A). Here the
cytotoxic effects of the drug combinations both with and without
concomitant IR of 4 gray (Gy) were assessed to determine radio-
sensitization (Fig. S1B). All of the PARP-PI3K combinations yielded an
increase in cell death with the addition of radiation. Of the PARP in-
hibitors tested, N combinations in particular resulted in greatly enhanced
toxicity with radiation. In contrast, olaparib, and veliparib combinations
resulted in minimal enhancement of radiation induced cell killing and
were eliminated from consideration.
Next, CI values were derived and evaluated to further narrow po-
tential combinations. The CI values were calculated by comparing the
response of cells to individual drugs versus combinations at specific
concentrations (Fig. S1C). These pairings can be synergistic (CI < 1),
additive (CI ¼ 1), or antagonistic (CI > 1). If the cellular response is
stronger at a combination concentration than the sum of responses to
each drug alone at the same concentration, it is considered synergistic.
Although talazoparib combinations were especially toxic, they were
largely not synergistic upon the addition of radiation (the graph curves
back up), similar to N with PI-103. With two viable combinations
remaining, the N-H (PARP-PI3K inhibitor) combination was selectedFig. 6. Alternative α-CTLA-4 dosing study. (A)
Treatment scheme similar to Fig. 5A with altered
α-CTLA-4 dosing time. (B) Relative tumor volume
curves for uncured mice responding to treatment
(n ¼ 3), * denotes p < 0.016. (C) Individual
growth curves for all (cured and uncured) E
POx þ IR þ α-CTLA-4 treated mice. (D) Individ-
ual growth curves for all (cured and uncured) N-
H POx þ IR þ α-CTLA-4–treated mice. The dotted
curve represents a non-responding mouse.
Responding, uncured mice in (D) show delayed
growth versus responding, uncured mice in (C).
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low concentrations, the N-H combination (Fig. 1A) elicited minimal
response but upon irradiation saw a sharp decrease in cellular viability
(Fig. 1B). Across a broad range of concentrations tested, N and H at a 1:1
ratio produced CI values less than one, indicating synergy (Fig. 1C). The
synergistic effects were especially prominent at higher fractions affected,
which is more relevant for anticancer agents [27]. Clinically, this
response profile would capitalize on the conformal nature of RT to induce
maximal response at the focal points of radiation and potentially mini-
mize off target toxicity. In addition to synergizing with N, H is an ideal
PI3K inhibitor for use in highly angiogenic cancers such as CRC, due to its
strong antiproliferative and antiangiogenic properties [18]. Moreover, H
is well suited for CRC based on reports of its ability to suppress
epithelial-mesenchymal transition and metastasis, and induce nec-
roptosis [28,29].
3.2. Novel HS-173 and niraparib combination induces immunogenic cell
death
ICD is a form of regulated cell death that leads to a local antitumor
immune response in an otherwise immune-suppressive tumor microen-
vironment [30,31]. The induction of ICD can trigger an adaptive immune
response thereby increasing immune cell infiltration. Select antineo-
plastic agents, such as oxaliplatin and cyclophosphamide, have been
found to trigger ICD [30,32]. The ability of a therapeutic to induce ICD
can be assessed through the expression of damage-associated molecular
patterns, such as calreticulin (CRT) [33]. Normally constrained to the
endoplasmic reticulum, CRT is translocated to the outer leaflet of the cell
membrane during ICD [32]. The translocation of CRT acts as an ‘eat me’
signal, stimulating dendritic cell phagocytosis, which subsequently ini-
tiates antigen presentation required for an immune response. Based on
this principle, immunogenic chemotherapy has recently been investi-
gated as a route to potentiate checkpoint blockade in multiple tumor
models [34–37].
To evaluate the ability of N-H to induce ICD, CT26 cells were treated
with the drug combination and stained for membrane CRT expression
(Fig. 2A). Colocalization of the cell membrane stain, WGA, with the CRT
stain indicated translocation. Here oxaliplatin, which is utilized in the
standard-of-care for CRC, was used as a positive control [32,38]. Fluo-
rescence images were taken, and the mean fluorescence intensity of CRT
was measured for each treatment. Dose optimization revealed that a
concentration as low as 0.8 μMof N-H (0.4 μMeach) significantly induces
external CRT expression, correlating to ICD (Fig. 2B). N-H demonstrated
greater CRT expression than the positive control, oxaliplatin, which
required a much higher drug concentration (50 μM) to trigger ICD.
After confirming that N-H induced ICD in vitro, we evaluated the
ability of this combination to influence immunogenicity in syngeneic
CT26 tumors. In this assay, ICD was identified by infiltration of immune
cells in necrotic areas, as described by Zhou et al. In this method, strong
infiltration was observed 24 h after intratumoral (IT) injection and
decreased by day 4 [39,40]. Here, DMSO (control) or N-H was admin-
istered IT to separate tumors implanted on the same mouse. After 24 h,
tumors were harvested, tissue was fixed, sliced, mounted, and stained for
hematoxylin and eosin (H&E). A slice from each tumor was imaged and
processed to quantify the percentage of hypoxia, especially in the
necrotic core of the tissue, for each treatment (Fig. S2). Based on this
evaluation, it appeared that the N-H resulted in slightly increased ne-
crosis as a fraction of total tissue area (6%) compared with DMSO
treatment (5%). As visualized in Fig. 2C–F, DMSO and N-H treated tu-
mors displayed not only a difference in tumor composition but also a
difference within the necrotic regions. In terms of tumor composition, a
clear reduction in tumor cell density, increased immune infiltration, and
increased necrosis were observed in the N-H treated tumors. The necrotic
regions—identified by an abundant pink staining—allow for identifica-
tion of ICD-associated alterations. When evaluating the necrotic regions
in Fig. 2C & D, the DMSO-treated tumor demonstrates peripheral8
immune presence (purple leukocyte) and minimal necrotic penetration
(dense pink with few purple leukocytes), while the N-H treated tumor
(Fig. 2E & F) has increased immune cell infiltration in the necrotic re-
gions. Taken together, this is further evidence that N-H triggers a local
immune response by inducing ICD.
3.3. Preparation and characterization of niraparib/HS-173
nanoformulations
After identification of a synergistic treatment regimen that induces
ICD, N and H were formulated using a poly(2-oxazaline) (POx)–based
amphiphilic triblock copolymer to improve overall drug delivery.
Numerous studies have revealed physiological benefits of using POx over
the classically used alternative polyethylene glycol (PEG), including
higher in vivo stability and favorable controlled drug release [20,21,41,
42]. Furthermore, POx are less immunogenic than PEG, allowing for
repeat dosing [43,44]. Our previous report on the POx polymer A-pol-
y(2-benzyl-2-oxazoline)-A (A-PBzOx-A) suggested it effectively encap-
sulates highly hydrophobic drugs with aromatic character in small
monodisperse micelles with moderate stability [45]. We therefore hy-
pothesized that A-PBzOx-A would effectively encapsulate the hydro-
phobic and aromatic PARP (N) and PI3K (H) inhibitors as well. Before
this report, A-PBzOx-A had not been tested in vivo, but in vitro no negative
effect on the cell viability in primary human dermal fibroblasts was
observed, suggesting good cytocompatibility [45]. In addition, similar
POx-based ABA triblock copolymers have been shown to be biocompat-
ible [21].
The nanoformulations introduced in this report readily self-assemble
via solvent-exchange in an aqueous environment due to the amphiphilic
nature of the polymer. A-PBzOx-A is a triblock copolymer with an ABA
arrangement where 2 hydrophilic poly(2-methyl-2-oxazoline) (‘A’) units
sandwich a hydrophobic and aromatic poly(2-benzyl-2-oxazoline) (‘B’)
unit. Briefly, N and H were solubilized in DMSO and mixed with A-PBzOx-
A in ethanol. This organic phase was then diluted in PBS, at which point
drug-encapsulating micelles spontaneously formed, and were subse-
quently purified from free drug, polymer, and solvent by centrifugal
nanofiltration (Fig. 3A). The resulting micelles were found to be stable for
a week at room temperature and do not experience changes in size or drug
loading after lyophilization and resuspension (Fig. S3). The micelles have
an average hydrodynamic diameter of 20.8 nmwith a polydispersity index
less than 0.2 as determined by DLS (Fig. 3B & S4). Such small size can be
considered particularly promising for hard to penetrate tumors with dense
stroma [46]. TEM confirmed the presence of spherical micelles with a size
of approximately 14 nm (Fig. 3C). Interestingly, the morphology of the
particles is altered with drug loading; empty micelles (E POx) have a mix
of wormlike and spherical micelles, whereas drug-loaded (N-H POx) boast
more spherical but somewhat bigger micelles (Fig. S4). Such morphology
changes with drug loading are not uncommon and have been reported
previously for similar POx-based micelles [47,48].
As small molecule drug carriers, POx polymers have been cited for
highly efficient encapsulation of taxanes and many other compounds of
particularly low water solubility [21,49]. Here for the first time, we
showed that POx are excellently suited for encapsulating the DDR in-
hibitor class as well. Evaluation of drug loading by HPLC revealed high
encapsulation efficiencies and loading capacities of N and H in the POx
micelles (Table S1). These micelles achieved a 5-fold greater molar
loading capacity with 8.4 times less polymer (5 mg/mL) than previous
poloxamer-DDR inhibitor formulations [15]. Importantly, this enhanced
formulation will potentially increase the amount of drug delivered to the
tumor and dramatically reduce formulation-associated toxicity. To that
end, the plain POx formulation (empty POx; E POx) was evaluated for
cytotoxicity and found to be nontoxic across a broad range of concen-
trations. Furthermore, encapsulation did not appear to affect the toxicity
of the N-H combination with or without radiation (Fig. 3D).
Investigating the influence of pH on the release of drug from our
formulation revealed differing profiles for the two drugs. N-H drug
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pH), 6.8 (tumor microenvironment pH), and 7.4 (blood pH). At each pH
N reached 80% release within the first 24 h, whereas H only reached
~10% release after 24 h, with maximum release of 33% at pH 7.4 at 2
weeks (Fig. 3E, S5). Although both drugs display similar hydrophobicity,
release appears to be highly pH dependent with peak HS-173 release
occurring at pH 7.4 and peak N release occurring at pH 5.5. Importantly,
while release in a cell-free system is slow and not complete, data pre-
sented in Fig. 3D clearly show that drug is reaching the target in the
presence of cells, likely via endocytosis. This demonstrates the limited
use of drug release studies in a simple dialysis bag setup.
3.4. Clonogenicity and DNA damage
After formulation, the ability of free and encapsulated N-H to induce
DNA DSB, which may contribute to tumor immunogenicity, was evalu-
ated. Both N and H act as cell cycle inhibitors, stalling cells in the most
radiosensitive phase, G2/M [18,50]. This cell cycle phase is considered
more radiosensitive because DNA is condensed, and IR can induce more
damage in a single track, reducing the radiation dose needed to cause the
same level of DNA damage [51]. Furthermore, H has been shown to
inhibit DNA damage repair kinases ataxia-telangiectasia mutated (ATM)
and DNA-dependent protein kinase catalytic subunit (DNA-PKcs), which
initiate a DSB signaling phosphorylation cascade [52]. Niraparib, on the
other hand, prevents the repair of SSBs by inhibiting PARP [50].
Together, H and N prevent effective DNA repair, leading to accumulation
of breaks after radiation.
To evaluate DDR inhibition in CRC, the radiation sensitizing potential
of N-H was evaluated in vitro by monitoring the induction of DSBs and
clonogenic survival. Untreated CT26 cells and CT26 treated with carrier
(E POx), drug (N-H), or drug formulation (N-H POx) with or without
radiation were evaluated by both microscopy and flow cytometry to
determine the extent of DSB induction using the surrogate marker,
γH2AX [53]. For microscopy, fluorescence images of the treated and
stained cells were taken and then the γH2AX were quantified per nuclei
(Figs. S6A–B). As observed by both microscopy and flow cytometry,
administration of N-H or N-H POx and radiation results in an increase in
both number and intensity of DSBs compared with radiation alone or
with E POx, demonstrating the radiosensitization potential of N-H
(Fig. 4A–C). In addition, by microscopy, the frequency of the γH2AX stain
is slightly higher in cells treated with N-H POx compared with N-H,
indicating minimally more DNA damage is inflicted when the drugs are
formulated (Fig. 4A–B). The slight increase in DNA damage may suggest
that the POx formulation is either increasing therapeutic uptake or may
be participating in the prevention of DNA damage repair, despite a lack of
observed toxicity. Reportedly, numerous amphiphilic POx micelles are
quickly endocytosed with distribution throughout the cell, but particu-
larly in the perinuclear region, the proximity of which may explain
enhanced DNA damage in the nanoformulation [54]. By in vitro analysis,
the hydrophilic, uncharged corona of the micelles facilitated comparable
CT26 cellular uptake of POx micelles loaded with Cy7.5 dye (Cy7.5 POx)
relative to free dye (Fig. S7). The small size of these micelles does not
appear to hinder their uptake compared with free drug, supporting the
microscopy data showing increased γH2AX with N-H POx. Contrastingly,
analysis by flow cytometry showed equivalent γH2AX intensity for N-H
and N-H POx (Fig. 4C); however microscopy data are more likely to
include dead cells thus making it more reliable when understanding the
induction of DNA DSBs.
Then, the clonogenic assay was used to assess reproductive cell death
after IR and cytotoxic treatments. Cells are plated at low density, then
exposed to drugs and increasing doses of radiation, and monitored for
colony formation. In this experiment, cells were incubated with N-H and
N-H POx at equal concentrations for 24 h before radiation to assess the
impact of micellar delivery. The survival curves in Fig. 4D indicated that
N-H POx is more effective than N-H free when exposed to radiation,
supporting the above γH2AX microscopy results. Coencapsulation allows9
a greater chance that both drugs reach the same cell rather than separate
cells, which could account for increased synergistic efficacy [41,55-57].
When evaluating the influence of H POx or N POx versus N-H POx, we see
that there is a decrease in SF when the drugs are treated together, sug-
gesting sufficient drug release for synergistic radiation sensitization
(Fig. S8).
3.5. Efficacy of multimodal combination therapy
Upon validation of in vitro efficacy, multimodal (PARP-PI3K, RT, and
ICB) therapy was evaluated in tumor-bearing BALB/cmice. Animals were
implanted subcutaneously with CT26 cells, and tumors were allowed to
develop for seven days until palpable. Seventy-six mice were then ran-
domized into eight treatment groups (four therapy arms delivered with
or without radiation) as outlined in the full experimental design (Fig. S9).
Four of these groups received intraperitoneal CTLA-4 antibody (α-CTLA-
4) injections five days before additional treatment was initiated (Fig. 5A).
From each treatment group, four mice were randomized to the treatment
efficacy/safety study to be sacrificed on the day the first mouse reached
an endpoint. The remaining mice in each treatment group were ran-
domized into the survival study, where sacrifice occurred for each mouse
independently when they reached an endpoint. On day 0, micelle
(3.57 mg/kg H, 3.69 mg/kg N, 34.1 mg/kg POx) and radiation (1 Gy)
treatments commenced and were repeated every other day for a total of
three doses each. Tumor growth for all mice was monitored by caliper
measurements until the first animal met an endpoint criterion (average
tumor diameter greater than 20 mm or ulceration), which occurred on
day 14.
N-H POx was administered in three relatively low doses to leverage
the drug synergy and ICD observed previously. Here, treatment efficacy is
assessed against the carrier (E POx) control for comparison. Utilizing this
conservative drug treatment, N-H POx and N-H POx þ IR treatment
groups did not show significant benefit on the basis of relative tumor
volume measurement (Fig. 5B, S10). However, upon evaluation of
endpoint (day 14) tumor mass, N-H POx appears to vastly increase the
number of mice responding to α-CTLA-4 therapy and to a lesser extent the
number of mice responding to IR (Fig. S11). Despite the lack of overall
improved tumor growth control of N-H POx alone or added to radiation,
histologic evaluation of N-H POx–treated tumors demonstrate tissue-
level differences in comparison to the carrier (Fig. 5C and S12-14). To
visualize these differences, tumors were harvested at tumor efficacy/
safety study end (day 14), formalin-fixed, paraffin-embedded, and
stained to visualize hypoxia (H&E), apoptosis (CC3), and proliferation
(Ki67). The percentage of stained area relative to the whole tumor slice
was quantified, with the N-H POx–treated tumor showing higher per-
centage of both hypoxic/necrotic tissue and apoptotic tissue compared
with E POx (Fig. 5C, S12). Further comparison of these two groups
revealed a slight decrease in Ki67 staining, indicating a decrease in tissue
proliferation. Previous reports have noted that HS-173 acts as an anti-
angiogenic agent which potentially accounts for the increase in hypoxia,
as well as a decrease in Ki67 for N-H POx–treated tumors [18,58]. In
addition, N-H POx induced beneficial histological changes to α-CTLA-4
treated mice. The addition of N-H POx to the α-CTLA-4 treatments
reduced hypoxia and increases apoptosis. N-H Pox þ α-CTLA-4 did,
however, result in the highest proliferation of the α-CTLA-4 treatments,
but the triple combination showed the least Ki67 stain, potentially
indicating that the combination of the three treatment modalities is
preferential (Figs. S13 and S14). Overall, histological analysis demon-
strated tissue-level differences between control and drug-treated tumors
which are not evident by evaluation of tumor growth curves. This in-
dicates that administering N-H POx may be a promising strategy to
potentiate ICB.
Although tumor size control was not observed with N-H POx treat-
ments under this treatment schedule, the α-CTLA-4 combination treat-
ments proved very effective. Here, we also note that α-CTLA-4 therapy
alone was efficacious and demonstrated enhanced tumor control over
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administration (250 μg seven days after tumor implantation) alone did
not influence CT26 tumor response or survival [59]. Comparatively, we
observed that the E POx þ α-CTLA treatment (green curve) exhibited
noticeable tumor control in comparison with carrier (E POx) alone.
Furthermore, the addition of either N-H POx (brown), IR (purple), or
their combination to α-CTLA-4 (navy) all resulted in reduced rate of
tumor growth compared with E POx þ α-CTLA-4 (green) at day 14
(Fig. 5B).
To further assess tumor control, relative tumor size measurements
were continued for the ICB-treated cohort of animals in the survival study
(Fig. 5D). This extended time frame allowed for greater separation be-
tween tumor growth curves to be observed between the treatment
groups. Here, data were only calculated for the entire treatment group
until the first animal reached endpoint criteria to maintain statistical
values (n  4, Fig. S9C). In the absence of IR, after 25 days, mice treated
with N-H POx þ α-CTLA-4 showed reduced tumor growth rate compared
with those treated with the carrier, E POx, þ α-CTLA-4. Although tumor
growth curves suggest a potential advantage with the multimodal ther-
apy, comparison is limited by the death of an E POx þ IR þ α-CTLA-4
mouse at day 28.
Ultimately, this initial dosing schedule of N-H POx did not extend
survival over E POx for non-ICB treatment groups, with median survival
of 14 days for both groups (Fig. S15). While the addition of radiation in
these non-ICB groups slightly increased survival, there was no additional
benefit when drug was administered (median survival 18 days for both).
The addition of ICB demonstrated a significant increase in survival
regardless of additional agents used. However, the micelle
formulation þ α-CTLA-4 (brown) did provide a survival benefit over the
POx carrier þ α-CTLA-4 (green), increasing median survival from 33.5 to
43 days (Fig. 5E). Furthermore, the additional benefit of including IR in
the treatment regimen was clearly demonstrated by both POx (E and
N–H) þ α-CTLA-4 treatments as median survival increased to 37 and 53
days, respectively.
3.6. Efficacy of a later anti-CTLA-4 dose administration
To elucidate the effect of N-H POx þ IR on α-CTLA-4 efficacy, the
POxþ IRþ α-CTLA-4 treatments were repeated with the same ICB dosing
schedule as aforementioned (5 days) and a delayed administration (0
days) coinciding with the start of POx and IR (Fig. 6A & S16). In the
aforementioned study, the efficacy of α-CTLA-4 overshadowed sensiti-
zation with multimodal therapy. Delaying ICB administration allowed for
the development of a more established tumor that may be less likely to be
controlled by ICB and RT alone. In mouse models, dosing too early with
α-CTLA-4 may deplete regulatory T cells (Tregs) such that the tumor is
minimized or cured with combined radiation/α-CTLA-4 before any
additional treatment can be administered and evaluated. As mentioned
previously, reports have demonstrated the benefits of administering
α-CTLA-4 before RT [34]. Tregs dampen the immune response to radia-
tion and may have served to make the previous α-CTLA-4 þ radiation
treatments (purple and navy curves in Fig. 5B) more efficacious. How-
ever, clinically, patients with late-stage CRC are the patient population
most often treated with immunotherapy, so the treatment of early-stage
tumors with ICB may not accurately reflect clinical routines.
Thus, as the timing of immune checkpoint inhibitor administration
may influence therapeutic efficacy, we investigated a later (day 0) ICB
administration. Dosing at the later time point resulted in increased tumor
control for the uncured, responding mice treated with N-H POx combi-
nation versus the E POx, further supporting the use of the multimodal
approach (Fig. 6B). At days 31 and 35, the difference in relative tumor
volume between the two treatments became significant, before the first
mouse reached an endpoint on day 35. In addition, the N-H POx com-
bination with α-CTLA-4 (day 0) was able to delay tumor growth, as
evinced in the individual tumor growth curves in Fig. 6C–D with the
exception of an individual non-responder in this treatment group.10Tumors of mice treated with E POx þ α-CTLA-4 (yellow curves) start to
rapidly grow at day 25, while that level of growth is delayed to day 45 for
N-H POx combination mice (pink curves). As expected, mice treated with
α-CTLA-4 on day 5 and either formulation (N-H POx or E POx) saw
extremely high cure rates reflecting the need to delay ICB administration
to elucidate the effects of incorporating N-H into the therapy regimen
(Fig. S17).
While the tumor growth for uncured mice was controlled by the
multimodal treatment, the cure rate was not altered with either α-CTLA-4
timing. Early α-CTLA-4 (day 5) resulted in 5 of 7 mice cured in each
arm, and late α-CTLA-4 (day 0) led to 4 of 7 in the E POx arm, and 3 of 7
in the N-H POx arm (Table S2A). Ultimately, the cure rate and tumor
growth control were high with α-CTLA-4 alone, which suggests lowering
the α-CTLA-4 dose would likely emphasize the effect of the N-H POx
treatment compared with controls. Finally, the durability of these two
combination treatments was analyzed by challenging cured mice with
150,000 CT26 cells on day 58. A small increase in the durability of cure
was observed in mice that received N-H POx compared with E POx for
early administered α-CTLA-4 (Table S2B).
3.7. Toxicity
Multimodal therapy provides an appealing approach to reduce indi-
vidual dosing of drug, radiation, and immunotherapy to improve overall
safety [60]. To evaluate the safety of this regimen, CT26 tumor-bearing
mice receiving the treatment outlined in Fig. 5A, were sacrificed at 14
days to collect blood, organs, and tumors for analysis.
As the DDR inhibitors used in this study can result in myelosup-
pression leading to dose-limiting toxicities, such as anemia, neutropenia,
and thrombocytopenia, and α-CTLA-4 often cause neutropenia as well,
we investigated the ability of our nanoformulated combination therapy
to reduce such side effects. To assess general overall health, blood
chemistry and CBC were run and demonstrated no significant deviation
from the E POx control (Fig. 7A–B). Importantly, the only deviation
observed was a decrease in aspartate aminotransferases (ASTs) in N-H
POxþ IRþ α-CTLA-4–treated mice (Fig. 7B) and an increase for the non-
α-CTLA-4 mice treated with IR and/or N-H POx (Fig. S18A–B). AST,
along with alanine transaminase (ALT), is indicative of liver function,
and increased expression can indicate liver damage; however the AST
levels of all treatments were within a standard range (IDEXX labora-
tories). This, along with data supporting proper kidney function indicate
that this treatment regimen is well-tolerated (see blood urea nitrogen
(BUN) in Fig. 7B and S18B).
In addition to blood markers, toxicity was also monitored by evalu-
ating body and organ weight. In Fig. 7C, regardless of treatment group,
weight loss indicating gross toxicity was not observed. Furthermore,
minimal variation in organ weight is observed between treatment groups
(Fig. S19). Interestingly, therapeutic intervention (N-H POx, E POx þ IR,
and N-H POx þ IR) presented a significant reduction in spleen weight as
compared with the control, E POx. We attribute the reduced spleen
weight in these groups to tumor control, as tumor growth triggers
splenomegaly, an accumulation of macrophages and neutrophils [61].
Finally, H&E staining of the harvested organs was performed to further
examine the safety of treatment (Fig. 7C & S20). In agreement with the
blood and weight data, the H&E images demonstrate no evidence of
toxicity and minimal variance between treatment groups with the
exception of the livers. Liver histology demonstrated cytoplasmic
vacuolization, which can be indicative of tissue damage and possibly a
result of exposure to therapeutic agents [62]. Interestingly, treatment
with the therapeutic N-H POx decreases liver cytoplasmic vacuolization.
Even more surprisingly, vacuolization appears to be further decreased
when N-H POx is combined with additional agents, demonstrating the
greatest reduction after N-H POxþ IRþ α-CTLA-4 treatment. Although it
is unclear what exactly induces the vacuolization and whether it is
harmful, one possible mechanism for this observed decrease in vacuoli-
zation is reported to be PARP inhibitor administration [15,63]. Overall,
Fig. 7. In vivo safety. (A) CBC results from
tumored mice treated after therapeutic
regimen in 5A. Counts in K/μL except red
blood cells (RBC). (B) Clinical chemistry
evaluation (BUN, total protein (TP), ALT,
AST) demonstrates the absence of organ-
based toxicity for all treatment groups. *
denotes significance (p < 0.05) compared
with the E POx control. (C) Histologic ex-
amination of H&E stained tissues (heart,
lungs, liver, kidneys, and spleen) harvested
from mice after therapeutic regimen in 5A
further confirm the absence of treatment-
based toxicity. Scale bar (200 μm) is repre-
sentative for all images. Arrows indicate
areas of hepatic vacuolization. CBC, com-
plete blood count; ALT, alanine trans-
aminase; AST, aspartate aminotransferase;
BUN. blood urea nitrogen.
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not result in any appreciable toxicity within the described treatment
protocol.
4. Conclusion
Immune checkpoint blockade has been very promising for metastatic
CRC. However, clinical application is limited by the toxicity and minimal
response in nonimmunogenic tumors. Herein, we proposed a modest drug
dosing schedule, with efficacy contingent on a combination of radiation,
immunotherapy, and small-molecule inhibitors. By conscientiously
combining the inhibitors with radiation and immunotherapy, the doses of
all four agents can be lowered, potentially reducing chemoresistance and
dose-limiting toxicities. We screened for an optimal radiosensitizing,
synergistic PARP/PI3K combination, followed by formulation for
increased drug delivery, and validated the combination in vitro by
assessing the DNA damage, drug release, toxicity, and ability to induce
ICD. The novel N-H combination was found to increase DNA damage in
CT26 cells and sensitize them to radiation in vitro, while simultaneously
inducing ICD at a low drug concentration. Upon initial in vivo investiga-
tion, early dosage of α-CTLA-4 masked the effects of the multimodal
therapy, whereas the N-H combination resolutely demonstrated a sensi-
tizing effect in the murine CRCmodel when α-CTLA-4 was administered at
a later time point. Despite a total dose of niraparib 7-fold lower than the11clinical daily MTD, niraparib in synergistic combination with HS-173 was
able to inhibit tumor growth and trigger ICD. This model indicates first,
the promise of the PARP-PI3K combination for CRC, and second, the value
of applying immunotherapy agents not only as mono- or dual
therapies but as multipronged therapies working in concert.
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